Actively Recruiting
Phase I Open-Label Study of Oral ABSK211 to Assess Safety and Efficacy in Advanced Solid Tumors with KRAS Alteration
Led by Abbisko Therapeutics Co, Ltd · Updated on 2026-09-04
247
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ABSK211, an oral drug, in participants with advanced solid tumors that have KRAS genetic alterations. This phase I, first-in-human, multicenter, open-label study aims to assess the safety, tolerability, pharmacokinetics PK, and dosage optimization of ABSK211. The study includes participants with locally advanced or metastatic solid tumors harboring KRAS alterations and good performance status. The study begins with a dose escalation phase where participants receive a single dose of ABSK211 followed by continuous daily dosing in 21-day treatment cycles to evaluate safety and PK. After determining recommended doses for expansion, the study moves to an expansion phase where participants receive ABSK211 at those doses to further assess safety and efficacy. Participants in the expansion phase take the drug orally once daily. Participants will be monitored for dose-limiting toxicities, adverse events, and serious adverse events from the start of treatment until 30 days after the last dose. Pharmacokinetic measures such as maximum concentration, time to maximum concentration, and drug clearance will be assessed. Efficacy outcomes including objective response rate, duration of response, disease control rate, progression-free survival, and overall survival will be evaluated up to 24 months. The study duration extends until June 2030, with ongoing safety and outcome assessments throughout.
CONDITIONS
Brief Title
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
Research Team
L
Lijun Zheng, Master
J
Jiaojuan He, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here